Tolvaptan Teva Training For Healthcare Professionals

Information for healthcare professionals in the UK

Tolvaptan Teva is indicated to slow the progression of cyst development and renal insufficiency of autosomal dominant polycystic kidney disease (ADPKD) in adults with CKD stage 1 to 4 at initiation of treatment with evidence of rapidly progressing disease. 01

Teva, in conjunction with the Medicines and Healthcare products Regulatory Agency (MHRA), are providing healthcare professionals and patients with an educational programme on Tolvaptan Teva. This programme includes healthcare professional (HCP) training slides and educational materials for HCPs and patients.

Healthcare professionals are required to review the training slides and accompanying educational materials provided on this website and confirm completion of this training by registering their details with Teva. Healthcare professionals will be reminded to refresh this training annually.

Tolvaptan Teva Training Materials

These materials provide important safety information on the risks of Tolvaptan Teva treatment, including liver toxicity, pregnancy prevention, monitoring requirements, dose and method of administration information, as well as the process for reporting adverse events.

This training does not replace the Summary of Product Characteristics (SmPC), which should be read thoroughly before prescribing or dispensing Tolvaptan Teva.  Patients should also be advised to read the Patient Information Leaflet (PIL). The SmPC and PIL for Tolvaptan Teva can be found at www.medicines.org.uk/emc.

Training Slides

 

Please verify that you have read and understood these training slides by clicking the ‘Confirm Training Completion’ button below and completing the form. Your contact details will be held securely by Teva for the sole purpose of facilitating refresher training on Tolvaptan Teva on an annual basis, as requested by the MHRA. For more information please read our Privacy Policy.

Confirm Training completion

Healthcare Professional Materials

Healthcare Professional Educational Guide

Download

Prescriber Checklist

Download

Patient Materials

Healthcare professionals are requested to provide each new patient with a copy of these materials which can be downloaded and printed via the links below or alternatively hard copies are available on request by contacting Teva Medical Information at medinfo@tevauk.com or calling 0207 540 7117.

Patient/Carer Education Brochure

Download

Patient Alert Card

Download

Further information

If you require further information on Tolvaptan Teva please contact Teva Medical Information at medinfo@tevauk.com or call 0207 540 7117.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search ‘MHRA Yellow Card’ in the Google Play or Apple App Store.  

Adverse events should also be reported to Teva on 0207 540 7117 or medinfo@tevauk.com.

Pregnancy and pregnancy outcomes should also be reported using the same details provided above.


References:

  1. Back to contents.

    Tolvaptan Teva - Summary of Product Characteristics available at www.medicines.org.uk/emc

Date of preparation: August 2021
Reference: COB-GB-NP-00007